Literature DB >> 11435300

Receptor specificity in the self-renewal and differentiation of primary multipotential hemopoietic cells.

H Zeng1, M Masuko, L Jin, T Neff, K G Otto, C A Blau.   

Abstract

To determine whether cytokine-induced signals generate unique responses in multipotential hemopoietic progenitor cells, the signaling domains of 3 different growth factor receptors (Mpl, granulocyte-colony-stimulating factor [G-CSF] receptor, and Flt-3) were inserted into mouse primary bone marrow cells. To circumvent the activation of endogenous receptors, each signaling domain was incorporated into an FK506 binding protein (FKBP) fusion to allow for its specific activation using synthetic FKBP ligands. Each signaling domain supported the growth of Ba/F3 cells; however, only Mpl supported the sustained growth of transduced marrow cells, with a dramatic expansion of multipotential progenitors and megakaryocytes. These findings demonstrate that the self-renewal and differentiation of multipotential progenitor cells can be influenced through distinct, receptor-initiated signaling pathways.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11435300     DOI: 10.1182/blood.v98.2.328

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  13 in total

1.  JAK2, complemented by a second signal from c-kit or flt-3, triggers extensive self-renewal of primary multipotential hemopoietic cells.

Authors:  Shengming Zhao; Karen Zoller; Masayoshi Masuko; Ponlapat Rojnuckarin; Xuexian O Yang; Evan Parganas; Kenneth Kaushansky; James N Ihle; Thalia Papayannopoulou; Dennis M Willerford; Tim Clackson; C Anthony Blau
Journal:  EMBO J       Date:  2002-05-01       Impact factor: 11.598

Review 2.  Hematopoietic stem cell gene therapy.

Authors:  David W Emery; Tamon Nishino; Ken Murata; Michalis Fragkos; George Stamatoyannopoulos
Journal:  Int J Hematol       Date:  2002-04       Impact factor: 2.490

Review 3.  Selective expansion of transduced cells for hematopoietic stem cell gene therapy.

Authors:  Akihiro Kume; Yutaka Hanazono; Hiroaki Mizukami; Takashi Okada; Keiya Ozawa
Journal:  Int J Hematol       Date:  2002-11       Impact factor: 2.490

4.  Engineering macrophages to control the inflammatory response and angiogenesis.

Authors:  K V Eaton; H L Yang; C M Giachelli; M Scatena
Journal:  Exp Cell Res       Date:  2015-11-21       Impact factor: 3.905

5.  Growth factor receptors as regulators of hematopoiesis.

Authors:  Michael A Weinreich; Ingrid Lintmaer; Linlin Wang; H Denny Liggitt; Michael A Harkey; C Anthony Blau
Journal:  Blood       Date:  2006-08-10       Impact factor: 22.113

6.  Erythropoietin stimulates phosphorylation and activation of GATA-1 via the PI3-kinase/AKT signaling pathway.

Authors:  Wei Zhao; Claire Kitidis; Mark D Fleming; Harvey F Lodish; Saghi Ghaffari
Journal:  Blood       Date:  2005-10-04       Impact factor: 22.113

7.  A hyperactive Mpl-based cell growth switch drives macrophage-associated erythropoiesis through an erythroid-megakaryocytic precursor.

Authors:  Eyayu Belay; Chris P Miller; Amanda N Kortum; Beverly Torok-Storb; C Anthony Blau; David W Emery
Journal:  Blood       Date:  2014-10-24       Impact factor: 22.113

8.  The signaling domain of the erythropoietin receptor rescues prolactin receptor-mutant mammary epithelium.

Authors:  Cathrin Brisken; Merav Socolovsky; Harvey F Lodish; Robert Weinberg
Journal:  Proc Natl Acad Sci U S A       Date:  2002-10-15       Impact factor: 11.205

9.  Mobilization of CD34+ progenitor cells in association with decreased proliferation in the bone marrow of macaques after administration of the Fms-like tyrosine kinase 3 ligand.

Authors:  R Keith Reeves; Qing Wei; Patricia N Fultz
Journal:  Clin Vaccine Immunol       Date:  2010-06-16

10.  Expansion of multipotent and lymphoid-committed human progenitors through intracellular dimerization of Mpl.

Authors:  Hisham Abdel-Azim; Yuhua Zhu; Roger Hollis; Xiuli Wang; Shundi Ge; Qian-Lin Hao; Goar Smbatyan; Donald B Kohn; Michael Rosol; Gay M Crooks
Journal:  Blood       Date:  2008-01-03       Impact factor: 22.113

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.